10 / 24
Robertson J. Lancet 2016;388:2997-3005
Fulvestrant (N=230)
Anastrozole (N=232)
Median age, years (range)
64.0 (38–87)
62.0 (36–90)
Race, n (%)
White
175
(76.1)
174
(75.0)
Any prior chemotherapy, n
(%)
79
(34.3)
81
(34.9)
Advanced disease
36
(15.7)
43
(18.5)
Adjuvant / neoadjuvant
35 / 11
(15.2 / 4.8)
27 / 16
(11.6 / 6.9)
WHO performance status, n
(%)
0 / 1 / 2
117 / 106 /
7
(50.9 / 46.1 /
3.0)
115 / 105 /
12
(49.6 / 45.3 /
5.2)
Receptor status, n (%)
ER+ / PgR+
175
(76.1)
179
(77.2)
ER+ / PgR-
44
(19.1)
43
(18.5)
ER+ / PgR unknown
10
(4.3)
7
(3.0)
ER- / PgR+
1
(0.4)
3
(1.3)
ER- / PgR-
0
0
Overall disease classification,
n (%)
Locally advanced disease
28
(12.2)
32
(13.8)
Metastatic disease
202
(87.8)
200
(86.2)
Visceral disease, n (%)
135
(58.7)
119
(51.3)
Measurable disease, n (%)
193
(83.9)
196
(84.5)
FALCON
Características pacientes